{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:08:28Z","timestamp":1790708908946,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Singapore is considering subsidizing left ventricular assist devices (LVADs) for end-stage heart failure (ESHF) and uses cost-effectiveness evidence to inform the determination. Yet, no economic evaluation has thus far been conducted.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the lifetime cost-effectiveness of LVAD compared with optimal medical management for transplant-ineligible patients.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This economic evaluation used a Markov model to simulate survival, stroke incidence, other adverse events, and heart failure hospitalizations for a cohort of adult patients in Singapore with transplant-ineligible ESHF, most of whom were inotrope dependent. Latest LVAD mortality data from a randomized clinical trial were age-adjusted, and an indirect comparison of prior trial results was performed to estimate survival for inotrope-dependent and inotrope-independent patients. Costs were estimated (in 2023 Singapore dollars [SGD]) using cohort billing data from 2017 to 2022 and National Heart Centre Singapore LVAD charges. Statistical analysis was performed from December 2023 to July 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>HeartMate 3 LVAD (Abbott).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Health care costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) evaluated against a threshold of SGD 114\u202f000 (US $85 075) per QALY gained.<\/jats:p><\/jats:sec>Results<\/jats:title>At model initiation, the cohort had a mean (SD) age of 64 (12) years, and 78% (range, 68%-86%) of patients were inotrope dependent. In the base case analysis, LVAD yielded an additional 3.45 QALYs at an incremental cost of SGD 404\u202f678 (US $301 999), producing an ICER of SGD 117\u202f370 (US $87 590) per QALY gained for the transplant-ineligible population. The ICER differed for inotrope-use subgroups at SGD 106\u202f458 (US $79 446) per QALY gained for inotrope-dependent patients and SGD 174\u202f798 (US $130 446) per QALY gained for inotrope-independent patients (with 59% and 19% probabilities, respectively, of attaining high value). The inotrope-dependent ICER was sensitive to model input changes and structural assumptions, whereas the inotrope-independent ICER consistently exceeded the high-value threshold in scenario analyses. In threshold analyses, a 44% reduction in the total implantation price or a 54% reduction in the all-cause mortality hazard were required for LVAD to be high value for inotrope-independent patients. Confidence that the inotrope-dependent ICER is high value increased to 75% and 85% with respective 20% and 33% reductions in total implantation price.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this economic evaluation comparing LVAD with optimal medical management, LVAD was potentially high value for most transplant-ineligible patients who are inotrope dependent. Confidence in this result was improved with plausible price reductions, yet only extreme changes rendered LVAD high value for inotrope-independent patients.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.4483","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T15:30:37Z","timestamp":1744990237000},"page":"e254483","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Effectiveness of Left Ventricular Assist Device for Transplant-Ineligible Patients"],"prefix":"10.1001","volume":"8","author":[{"given":"Elisabeth M.","family":"Schaffer","sequence":"first","affiliation":[{"name":"Saw Swee Hock School of Public Health, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Giok Sim","family":"Su","sequence":"additional","affiliation":[{"name":"Health Services and Systems Research, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxing","family":"Chay","sequence":"additional","affiliation":[{"name":"Health Services and Systems Research, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Finkelstein","sequence":"additional","affiliation":[{"name":"Health Services and Systems Research, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"issue":"5","key":"zoi250197r1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/ejhf.779","article-title":"Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes.","volume":"19","author":"Gustafsson","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"zoi250197r2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2013.11.053","article-title":"The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.","volume":"63","author":"Ambrosy","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"zoi250197r3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ehf2.12036","article-title":"Heart failure in Southeast Asia: facts and numbers.","volume":"2","author":"Lam","year":"2015","journal-title":"ESC Heart Fail"},{"issue":"12","key":"zoi250197r4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.jacc.2020.01.034","article-title":"Evaluation for heart transplantation and LVAD implantation: JACC Council Perspectives.","volume":"75","author":"Guglin","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"zoi250197r5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.healun.2020.08.022","article-title":"Durable mechanical circulatory support across the Asia-Pacific region.","volume":"39","author":"Sivathasan","year":"2020","journal-title":"J Heart Lung Transplant"},{"issue":"20","key":"zoi250197r6","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term use of a left ventricular assist device for end-stage heart failure.","volume":"345","author":"Rose","year":"2001","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi250197r7","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","article-title":"Advanced heart failure treated with continuous-flow left ventricular assist device.","volume":"361","author":"Slaughter","year":"2009","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi250197r8","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1001\/jama.2022.16197","article-title":"Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial.","volume":"328","author":"Mehra","year":"2022","journal-title":"JAMA"},{"issue":"7","key":"zoi250197r9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jchf.2017.02.016","article-title":"Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results.","volume":"5","author":"Starling","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"4","key":"zoi250197r10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamacardio.2019.5323","article-title":"Association of clinical outcomes with left ventricular assist device use by bridge to transplant or destination therapy intent: the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) randomized clinical trial.","volume":"5","author":"Goldstein","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"2","key":"zoi250197r11","first-page":"1","article-title":"Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure.","volume":"19","year":"2004","journal-title":"Technol Eval Cent Assess Program Exec Summ"},{"issue":"1","key":"zoi250197r12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/CIRCHEARTFAILURE.111.962951","article-title":"Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.","volume":"5","author":"Rogers","year":"2012","journal-title":"Circ Heart Fail"},{"issue":"3","key":"zoi250197r13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1017\/S0266462313000238","article-title":"Cost-effectiveness of continuous-flow left ventricular assist devices.","volume":"29","author":"Neyt","year":"2013","journal-title":"Int J Technol Assess Health Care"},{"issue":"10","key":"zoi250197r14","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.cjca.2017.07.012","article-title":"Economic evaluation of left ventricular assist devices for patients with end stage heart failure who are ineligible for cardiac transplantation.","volume":"33","author":"Chew","year":"2017","journal-title":"Can J Cardiol"},{"issue":"2","key":"zoi250197r15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.healun.2021.11.014","article-title":"A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: a United Kingdom perspective.","volume":"41","author":"Lim","year":"2022","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"zoi250197r17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated Reporting Guidance for Health Economic Evaluations.","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"8","key":"zoi250197r19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/01.CIR.0000139862.48167.23","article-title":"Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).","volume":"110","author":"Stevenson","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"zoi250197r20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1161\/CIRCULATIONAHA.118.037231","article-title":"Comprehensive analysis of stroke in the long-term cohort of the MOMENTUM 3 study.","volume":"139","author":"Colombo","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"zoi250197r21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1161\/01.STR.0000047852.05842.3C","article-title":"Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year.","volume":"34","author":"Appelros","year":"2003","journal-title":"Stroke"},{"issue":"1","key":"zoi250197r22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1524-4733.2008.00425.x","article-title":"Utility estimates for decision-analytic modeling in chronic heart failure: health states based on New York Heart Association classes and number of rehospitalizations.","volume":"12","author":"G\u00f6hler","year":"2009","journal-title":"Value Health"},{"issue":"4","key":"zoi250197r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3767","article-title":"Health utility weighting of the modified Rankin scale: a systematic review and meta-analysis.","volume":"3","author":"Rebchuk","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"44","key":"zoi250197r24","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1093\/eurheartj\/ehz427","article-title":"A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.","volume":"40","author":"Mehra","year":"2019","journal-title":"Eur Heart J"},{"issue":"9","key":"zoi250197r25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022248","article-title":"Study protocol for a cohort study of patients with advanced heart failure in Singapore.","volume":"8","author":"Malhotra","year":"2018","journal-title":"BMJ Open"},{"issue":"21","key":"zoi250197r28","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.jacc.2014.03.016","article-title":"ACC\/AHA statement on cost\/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.","volume":"63","author":"Anderson","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"zoi250197r29","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/ehf2.13401","article-title":"Cost-effectiveness of left ventricular assist devices as destination therapy in the United Kingdom.","volume":"8","author":"Schueler","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"8","key":"zoi250197r30","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1097\/MAT.0000000000001211","article-title":"Cost-effectiveness of a small intrapericardial centrifugal left ventricular assist device.","volume":"66","author":"Silvestry","year":"2020","journal-title":"ASAIO J"},{"issue":"6","key":"zoi250197r31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jval.2024.02.013","article-title":"Understanding the National Institute for Health and Care Excellence severity premium: exploring its implementation and the implications for decision making and patient access.","volume":"27","author":"Njoroge","year":"2024","journal-title":"Value Health"},{"issue":"11","key":"zoi250197r32","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","article-title":"The Seattle Heart Failure Model: prediction of survival in heart failure.","volume":"113","author":"Levy","year":"2006","journal-title":"Circulation"},{"key":"zoi250197r33","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2147\/CIA.S323979","article-title":"Performance of prognostic risk scores in elderly Chinese patients with heart failure.","volume":"16","author":"Cheng","year":"2021","journal-title":"Clin Interv Aging"},{"key":"zoi250197r34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ijcard.2015.10.008","article-title":"Validation of the Seattle Heart Failure Model in Japanese heart failure patients.","volume":"203","author":"Shiraishi","year":"2016","journal-title":"Int J Cardiol"},{"issue":"9","key":"zoi250197r35","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jchf.2018.03.019","article-title":"Ambulatory inotrope infusions in advanced heart failure: a systematic review and meta-analysis.","volume":"6","author":"Nizamic","year":"2018","journal-title":"JACC Heart Fail"},{"key":"zoi250197r26","volume-title":"Complete Life Tables for Singapore Resident Population, 2022-2023","author":"Singapore Department of Statistics","year":"2024"},{"key":"zoi250197r16","unstructured":"Ministry of Health Singapore. Achieving more with less: Singapore\u2019s healthcare expenditure. 2018. April 2, 2024. Accessed March 11, 2025. https:\/\/www.moh.gov.sg\/newsroom\/statistics-on-government-expenditure-on-public-healthcare--subsidised-medical-care-for-citizens--prs-and-foreigners--and-healthcare-spend-by-government-and-individuals"},{"key":"zoi250197r18","unstructured":"Kwok? BWK, Yee? OH, Ping? CLS, . 2020 Clinical practice guidelines on the diagnosis and management of heart failure: a comprehensive updated guideline from the Heart Failure Society (Singapore). Accessed February 2, 2024. https:\/\/www.hfss.org.sg\/wp-content\/uploads\/2018\/07\/Singapore-Heart-Failure-Guidelines-2020.pdf"},{"key":"zoi250197r27","unstructured":"Agency for Care Effectiveness. Medical technologies evaluation: methods and process guide. March 2022. Accessed July 30, 2024. https:\/\/www.ace-hta.gov.sg\/docs\/default-source\/process-methods\/ace-med-tech-evaluation-methods-and-process-guide-(mar-2022).pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2832977\/schaffer_2025_oi_250197_1744392766.96003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T15:30:42Z","timestamp":1744990242000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2832977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.4483","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}